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Background: In cervical postoperative radiotherapy, the target volume is usually the same as the extension of the
previous dissection. We evaluated a protocol of selective irradiation according to the risk estimated for each
dissected lymph node level.
Methods: Eighty patients with oral/oropharyngeal cancer were included in this prospective clinical study between
2005 and 2008. Patients underwent surgery of the primary tumor and cervical dissection, with identification of
positive nodal levels, followed by selective postoperative radiotherapy. Three types of selective nodal clinical target
volume (CTV) were defined: CTV0, CTV1, and CTV2, with a subclinical disease risk of <10%, 10-25%, and 25% and a
prescribed radiation dose of <35 Gy, 50 Gy, and 66–70 Gy, respectively. The localization of node failure was
categorized as field, marginal, or outside the irradiated field.
Results: A consistent pattern of cervical infiltration was observed in 97% of positive dissections. Lymph node failure
occurred within a high-risk irradiated area (CTV1-CTV2) in 12 patients, marginal area (CTV1/CTVO) in 1 patient, and
non-irradiated low-risk area (CTV0) in 2 patients. The volume of selective lymph node irradiation was below the
standard radiation volume in 33 patients (mean of 118.6 cc per patient). This decrease in irradiated volume was
associated with greater treatment compliance and reduced secondary toxicity. The three-year actuarial nodal
control rate was 80%.
Conclusion: This selective postoperative neck irradiation protocol was associated with a similar failure pattern to
that observed after standard neck irradiation and achieved a significant reduction in target volume and secondary
toxicity.
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Squamous cell cancer of the head and neck is diagnosed
in 650,000 individuals annually worldwide and accounts
for 5-10% of all malignant tumors [1]. The region with
the highest incidence is Southern Europe, where there
has been a gradual reduction in oral cancer and an
increase in oropharyngeal cancer [2].
Squamous cell cancer of the head and neck follows a
consistent and well-defined locoregional growth pattern.* Correspondence: martinezcarrillo.miguel@gmail.com
1Department of Radiation Oncology, Virgen de las Nieves University Hospital,
Avda. Fuerzas Armadas 4, Granada 18014, Spain
Full list of author information is available at the end of the article
© 2013 Martínez Carrillo et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumThe therapeutic decision depends on the lymph node
metastatic status, because tumor control requires treat-
ment of both the primary tumor and involved regional
nodes [3].
Standard guidelines for selecting target volumes are
based on knowledge of neck tumor distribution and
dissemination patterns. The Memorial Sloan-Kettering
Cancer Center described the pattern of cervical lymph
node metastasis in 1077 naïve patients with head and
neck cancer after performing 1118 neck dissections
[4-6]. Neck dissection was performed in 343 of the 341
patients with a clinically N0 neck cancer, i.e., bilateral
dissection was only performed in two patients. Bilaterald Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Clinical and pathological features
Clinical n % Pathological n %
Gender Infiltration
Male 56 75 Vascular 7 9
Female 19 25 Perineural 13 17
Tumor location Histological grade
Oral cavity 58 77 G3 11 15
Oropharynx 17 23 G4 2 3
Performance status ECOG 0-1 70 93 Resection margin
Close 13 17
Infiltrated 9 12
Clinical stage Pathological stage
I 4 5 I - -
II 13 17 II - -
III 21 28 III 24 32
IVa 30 40 IVa 48 64
IVb 7 9 IVb 3 4
Clinical N+ 47 63 Pathological N+ 75 100
Extracapsular spread 31 41
Median age of 62 years; range, 39–78 years.
ECOG = Eastern Cooperative Oncology Group; N + = Positive lymph node.
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with clinically positive nodes. Metastatic disease was
confirmed in 33% of elective neck dissections and 82%
of therapeutic neck dissections. The distribution of patho-
logically confirmed metastatic lymph nodes varied
according to the primary tumor site. In clinically N0
patients, metastatic lymph nodes were generally observed
in levels I-III for oral cavity tumors (20%, 17% and 9%
respectively) and in levels II-IV for oropharyngeal tumors
(25%, 19% and 8% respectively). A similar pattern was
observed in the patients who underwent therapeutic neck
dissection except for a higher density of adenopathies and
significant pathologic infiltration of an additional level;
among tumors of the oral cavity, 44% were in level I, 32%
in level II, 16% in level III, and 3% in levels IV; in oropha-
ryngeal tumors, 15% were in level I, 71% in level II, 42% in
level III, 27% in level IV, and 9% in level V. Pathological
infiltration of level V was low, observing a single infiltration
of level V in only one patient; it was below 1% when a
single pathologically confirmed positive node was detected
in levels I-III but increased to 16% when a single positive
node was located in level IV. When more than one level
was infiltrated, the likelihood of level V involvement
progressively increased, reaching 40% when levels I-IV were
all involved. Pathological involvement of level I was
observed in only 2% of clinical N0 patients with oropharyn-
geal tumors, increasing to 15% after therapeutic dissection.
These observations illustrate the gradual and orderly infil-
tration of node levels in the neck.
Surgeons were the first to use the concept of selective
treatment, performing selective dissections of the neck
to remove only high-risk lymph node levels. This prac-
tice led surgeons to divide the neck into different levels
according to anatomical references that can be easily
identified during neck dissection procedures (i.e. major
vessels, muscles, cartilages), known as the Robbins clas-
sification [7,8]. Selective neck dissection is currently the
procedure of choice for elective neck surgery and for a
specific group of neck-positive patients (selected N1 and
N2 patients) [9] and is associated with a comparable
nodal relapse rate to that observed in patients undergo-
ing radical dissection [10-12].
The applicability of the Robbins classification to the
definition of radiation target volumes remains controversial.
The standardization of target volumes is challenging,
because the relevant anatomical-surgical references are not
always identifiable on CT or MR scans. References pro-
posed in the 1990s for the radiological definition of neck
lymph node levels were inconsistent [13-18], leading to the
publication of consensus guidelines for N0 patients in 2003
[19]. In 2006, Gregoire et al. [20] proposed a modification
of the definition of neck regions for postoperative radiation
therapy, which otherwise appears to have received little
research attention.Target volume dose-dependent toxicity (e.g., oromu-
cositis and dysphagia) can limit the correct uninter-
rupted administration of adjuvant radiation therapy [21].
Therapeutic compliance would be enhanced if target
volumes and, therefore, secondary toxicity could be
reduced while maintaining tumor control. Standardized
neck dissection by levels can yield data that allow clini-
cians to adapt target volumes according to the estimated
risk of involvement for each node level.Materials and methods
For this study, we recruited all consecutive patients diag-
nosed with squamous cell cancer of the oral cavity or
oropharynx between 2005 and 2008 who underwent surgi-
cal resection of the primary tumor, without gross residual
disease, including unilateral or bilateral neck dissection
with a report of histological results by neck level, and who
received postoperative radiation therapy prescribed by a
multidisciplinary team of head and neck specialists. Writ-
ten informed consent was obtained from all recruited
patients, and the trial was approved by the hospital ethics
committee (Clinical Research Ethical Committe Virgen de
las Nieves Hospital). Out of the 80 patients recruited, 5
were subsequently excluded after application of the
following exclusion criteria: receipt of <90% of the
planned radiotherapy dose (1 patient), interruption of > 2
weeks (1 patient), and the detection of cervical (2 patient),
or local (1 patient) relapse during the course of the
Table 2 Nodal surgical procedure
Cervical dissection (levels) Ipsilateral Contralateral Total
RND (I-V) 7 - 7
MRND (I-V) 33 5 38
SOHND (I-III) 30 9 39
LND (II-IV) 5 1 6
Total 75 15 90
Abbreviations: RND = radical neck dissection; MRND =modified radical neck
dissection; SOHND= supraomohyoid neck dissection; LND= lateral neck dissection.
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the patients in the final sample are described in Table 1.
Out of these 75 patients, 15 underwent both ipsilateral
and contralateral node dissection. The type of dissection
depended on the nodal stage, performing selective
dissection in N0-N1 patients and dissection of all levels
(I-V) in N2-N3 patients (Table 2).
Nodal levels were intraoperatively identified following
standard guidelines and then stained and delineated
using surgical clips. After en bloc resection, nodal levels
were coded and sent for individual histopathological
study with hematoxylin-eosin staining. Adenopathies >3
mm in diameter were identified, and a topographical
diagram was created of the involved levels, the number
and size of positive nodes, and the presence of extra-
capsular spread.
Following the standard protocol, postoperative radio-
therapy was administered to the site of the primary
tumor (close or infiltrated surgical margin, pT4, vascu-
lar/perineural invasion, histologically undifferentiated),
the dissected side of the neck (pN1 with perinodal inva-
sion, skip metastases or inadequate dissection, i.e., total
nodal yield ≤ 5, pN2-N3), and the clinical N0 contrala-
teral non-dissected side of the neck with significant risk
of subclinical involvement (considered for ipsilateral
neck irradiation and/or primary in midline).
The clinical tumor volume (CTV) for elective neck
radiotherapy without dissection (clinical contralateral
N0) was delineated using an adaptation of consensus
guidelines [19] with the above-mentioned modificationTable 3 Selection of selective nodal clinical target volume (CT
Nodal CTV0
Subclinical disease risk <10%
Prescribed radiation dose <35 Gy (a)
Levels dissected Negative level with sufficient dissection N
Positive level without risk factors Adja
Levels not dissected - Ips
-
(a) Referred to mean dose < 35 Gy.
Abbreviations: ECS = Extracapsular spread; pN = pathological nodal stage.by Gregoire et al. for postoperative neck radiotherapy
[20]. This radiotherapy was administered to patients
with at least two involved lymph nodes or with one
involved lymph node generally associated with an
unfavorable prognosis (at this level we only identified
the infiltrated node, involved lymph nodes with a dia-
meter >3 cm, or any extracapsular spread at any other
dissected nodal level). N-pathological dissected levels
adjacent to nodal levels with extracapsular spread and/
or pN3 were considered high-risk levels. When the
involved lymph node was located at the boundary of two
levels, both levels were considered high-risk. Levels situ-
ated between two or more high-risk levels were included
in the target volume, regardless of their pathological
status.
According to these criteria and the estimated risk for
subclinical disease, we used three types of selective nodal
CTV (Table 3) and two types of standard nodal CTV (all
dissected neck levels) routinely used at our center for
comparison of the results.
The Pinnacle 8.0 version 3, 3D planning system was
used, and the treatment was administered by means of a
Varian Clinac-D 2100C linear accelerator equipped with
multileaf collimator. An isotropic margin of 5 mm was
applied to the respective CTVs to generate the appropriate
planning target volume (PTV). The dose variation in a
PTV was not allowed to exceed +7% or −5% of the
prescribed dose. Brain, brainstem, spinal cord, lens, retina,
optic nerves, optic chiasm, parotid gland, and mandible,
among other structures, were delineated on the CT image.
The prescribed dose to the PTV was 50 Gy to the
isocenter for PTV1 and a cumulative dose of 66–70 Gy
for PTV2. Concomitant cisplatin-based chemotherapy
was received by 36 patients with extracapsular spread
and/or positive surgical margin (100 mg/m2 cisplatin
every 3 weeks by 28 patients and 40 mg/ m2 weekly by 8).
Post-treatment neck CT examinations with intraven-
ous contrast were performed at 2, 6, 12, 18, 24 months
and then annually, or when a relapse was suspected.
Post-treatment nodal relapse was defined by the appear-
ance of an adenopathy in the neck. A nodal relapseV)
Nodal CTV1 Nodal CTV2
10%-25% >25%
50 Gy 66-70 Gy




cent negative level to nodal CTV2 (ECS and/or pN3)
ilateral: Non-dissected level adjacent to infiltrated
dissected level
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Figure 1 The radiologic imaging of nodal recurrence volume was co-registered with the pre-treatment CT data set used for treatment
planning. (A) DVH analysis of nodal failure “in field”. (B) DVH analysis of nodal failure “marginal field”. (C) DVH analysis of nodal failure “out-field”.
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study, and a new CT-simulation scan was performed
using the same thermoplastic mask and parameters
(isocenter, thickness and number of radiological slices)
to calculate the nodal relapse volume (NRV). After
obtaining the dose-volume histograms, nodal relapse
was classified as: within the irradiated field (>95% of
NRV within CTV1 or CTV2); within the margins of the
irradiated field (20%-95% of NRV within CTV1 or
CTV2); or outside the irradiated field (<20% of NRV
within CTV1 or CTV2) (Figure 1).Actuarial locoregional control and survival rates were
calculated by using the Kaplan-Meier method. SPSS
version 19 (IBM, Chicago IL) was used for all data
analyses.
Results
As depicted in Figure 2, 1,545 lymph nodes were
dissected: 1,294 nodes in ipsilateral dissections and 251
in contralateral dissections, distributed over the five
neck levels. Metastasis to at least one of the examined
lymph nodes was observed in all 75 ipsilateral necks
Ipsilateral Contralateral
Figure 2 Quantification of nodal levels dissected.
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tive) levels, i.e., a mean of 1.6 positive ipsilateral node levels
per patient (1–4). These 121 levels contained a total of 183
metastatic adenopathies, i.e., a mean of 1.5 positive nodes
per involved level (1–7). Level II was the most frequently
involved in the oral cavity (16/31) and oropharynx (37/90)
tumors; among the oral cavity cancers, level Ib was most
frequent in tumors of the floor of the mouth (14/27). A
regular neck dissemination pattern to levels I to III was
observed in 73 (97%) of the 75 ipsilateral dissections,
starting in levels Ia/Ib in 39 dissections, level II in 30, and
level III in 4. In the other two ipsilateral dissections, one
showed involvement of levels Ib, II and IV but not of level
III and the other involvement of levels II and V but not of
levels III or IV.
Only one case of metastasis to a contralateral node
was detected (to levels II and Ib).
Post-treatment nodal failure was observed in 15 of the
75 patients, local failure in 9, distal failure in 7, and a
second primary tumor in 3 (Table 4). All nodal relapse
cases were located in the ipsilateral dissected neck.
Nodal failure was within high-risk irradiated areas (nodal
CTV1, CTV2) in 12 patients, in a marginal area (nodal
CTV1/CTV0) in 1 patient, and outside the irradiationTable 4 Pattern of treatment failure
Failure n (%) Post-treatment months
Nodal failure 15 (20) 10.2 (6–19)
Local failure 9 (12) 11.4 (7–23)
Distal failure 7 (9) 11.7 (6–20)
Second primary tumor 3 (4) 25 (11–46)area (nodal CTV0) in the remaining 2 patients, who
therefore did not receive post-treatment radiation thera-
py in this zone (Table 5).
The dosimetric study of nodal failures revealed a mean
NRV of 4.4 cc (1.9-10.2 cc). Mean, minimal, and max-
imal doses were, respectively, 6518 cGy, 6420 cGy, and
6894 cGy for patients with nodal failure in the irradiated
field; 3091 cGy, 590 cGy, and 5101 cGy for those with
failure within the margins of the field; and 2357 cGy,
320 cGy, and 4421 cGy for patients with nodal failure
outside the radiation field (Table 5).
Out of the 75 patients in the study, 33 (44%) received
postoperative selective nodal irradiation, with a mean
reduction in target volume of 118.6 cc per patient (21.9
cc-234.7 cc), i.e., nodal CTV0, with a mean reduction of
1.8 levels per patient. Dose stratification by levels
allowed us to administer dose-escalated radiotherapy
from a dose of 50 Gy, only applying 66–70 Gy in high-
risk levels. Out of the total of 186 irradiated levels, 40%
received a high dose (66–70 Gy: nodal CTV2) and 60% a
low dose (50 Gy: nodal CTV1).
After a mean follow-up of 32 months, 45 patients
(60%) were alive and disease-free, 2 were alive with
disease (3%), 22 patients died from the tumor (29%), and(range) Prognostic factors Localization (n)
Age > 62 yrs (p 0.002) -



















1 II-III ipsilateral Nodal CTV2 6 9.1 6498.2 6980.0 6602.9
2 III-IV ipsilateral Nodal CTV2 12 3.45 6489.9 6995.9 6629.5
3 II ipsilateral Nodal CTV1 14 2.8 4399.0 6551.2 5554.1
(Nodal CTV2 marginal)
4 III ipsilateral Nodal CTV0 9 9.35 175.1 3113.2 1191.4
5 III ipsilateral Nodal CTV1 8 1.83 5685.5 7005.2 6535.1
II ipsilateral Nodal CTV2 8 2.51 6652.8 6741.6 6701.8
6 II ipsilateral Nodal CTV2 7 3.5 7009.1 7255.1 7149.8
7 V ipsilateral Nodal CTV0 19 3.1 195.0 5050.1 2789.8
8 Ib-II ipsilateral Nodal CTV2 8 3.35 6561.1 7171.2 6805.5
9 II-III ipsilateral Nodal CTV0 17 2.9 589.9 5101.0 3091.0
(nodal CTV1 marginal)
10 Ib ipsilateral Nodal CTV1 11 2.8 6491.0 7001.0 6682.2
II ipsilateral Nodal CTV2 11 1.9 4901.0 6281.2 5402.3
11 II ipsilateral Nodal CTV2 7 9.8 6595.3 6798.4 6639.0
12 Ib ipsilateral Nodal CTV2 7 2.9 6598.2 6792.0 6689.3
13 II ipsilateral Nodal CTV2 8 2.1 6601.4 6850.1 6602.2
14 Ib ipsilateral Nodal CTV2 11 2.8 6599.0 6899.4 6598.0
15 Ib ipsilateral Nodal CTV2 10 10.2 6278.7 7195.5 6658.9
Abbreviations: CTV0 = low-risk clinical target volume; CTV1 =moderate-risk clinical target volume;
CTV2 = high-risk clinical target volume.
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survival rates were 84% at 12 months and 79% at 36
months.Discussion
Following positive nodal dissection, standard target
volume radiotherapy includes all node levels considered
to be high-risk by the surgeon, coinciding with the
extent of the dissection and including retropharyngeal
lymph nodes, which are not usually dissected [13,22].
Selective nodal irradiation hypothetically offers a decrease
in target volume with no increase in marginal failures,
considering the neck as a set of volumes for mapping
high-risk neck regions. Evidently, selective nodal irradi-
ation would not significantly reduce the target volume in
patients with bulky metastasis and/or multiple neck level
involvement.
It proved possible to administer postoperative selective
nodal irradiation to nearly half of the present series of
75 head-and-neck cancer patients, obtaining a significant
reduction in target volume. Dose-volume histogram
analysis showed that the dose for recurrent nodal disease
was comparable to or higher than the target prescrip-
tion. Nodal failure was predominantly observed in thehigh-dose volume (CTV2), suggesting the need to dis-
cern a radiation-resistant subpopulation within CTV2.
Given the likely relationship of radiotherapy-induced
toxicity with the target volume and administered dose,
this toxicity might be significantly reduced by a selective
irradiation approach. In the TROG 91:01 trial, which
included 350 head and neck cancer patients, Poulsen
et al. [23] reported that the target volume in the second
phase of treatment had the strongest influence on the
development of odynophagia and need for aggressive
nutritional intervention (gastrotomy or insertion of naso-
gastric tube), finding that the likelihood of developing
grade-4 (G-4) odynophagia was 36% when the volume
was > 82 mm and 16% when it was <18 mm (p = 0.0001).
In our series, acute toxicity most frequently presented
as mucositis and dysphagia in the patients undergoing
radiotherapy (G-3 mucositis in 16%; G-3 dysphagia in
14%) and in those treated with concomitant chemora-
diotherapy (G-3 mucositis in 27%; G-4 mucositis in 6%;
G-3 dysphagia in 21%). Out of the 75 patients, only 1.3%
received <95% of the prescribed radiation dose; the dose
administered to neck volumes represented 98.4% of the
prescribed dose (nodal CTV1: 99.6%, nodal CTV2: 98%),
90.6% completed their radiation therapy plan with no
more than one day of interruption, and all completed
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3.5% of interruptions were secondary to toxicity, a lower
percentage than in previous reports [24,25]. In the study
based on SEER’s (Surveillance, Epidemiology and End
Results) [26] database, which included 5,086 patients
with head-and-neck cancer, 29.6% of the patients treated
with surgery and radiotherapy showed treatment discon-
tinuity and/or non-adherence (33.3% of those with oral
cancer and 33.5% of those with oropharyngeal cancer).
The development and incorporation of postoperative
selective nodal irradiation techniques into clinical practice
requires the routine performance of neck dissection by
level. The possibility that the results may be inferior to
those obtained with en bloc dissection was refuted by
Upile et al., who found no difference in total yield between
specimens sent to the histopathologist en bloc or divided
into levels [27].
The variability in the number of nodes obtained from
neck dissection can only be partially attributed to ana-
tomical differences among patients, given that previous
studies indicated a minimum of 28 nodes on each side
of the dissected neck [28]. The primary cause of nodal
variability is generally related to the surgical technique.
Although the boundaries of radical dissection are
defined in consensus guidelines [7,8], they may be modi-
fied by surgeons based on their own professional expe-
rience or because the terminology used to define the
different types and dimensions of neck dissection is incon-
sistent. A substantial reduction in nodal variability can be
expected if surgeons strictly adhere to the anatomical
boundaries established in consensus guidelines for dissec-
tion procedures. The number of nodes is usually lower in
selective procedures, such as supraomohyoid or lateral
dissection, due to the smaller number of dissected levels
[9-12]. The amount of lymphoid tissue dissected for
histological study by level should always be the same,
regardless of the type of dissection (radical, modified, or
selective). In the present series, there was a minimal
variability in the mean number of nodes identified in each
level as a function of the type of dissection.
The histopathological report plays a key role in the
assessment of the dissected specimen. The standard
procedure for studying a dissected node after hematoxylin-
eosin staining is to remove a longitudinal section for exa-
mination under light microscopy to detect metastatic
deposits [29]. These partial findings are then extrapolated
to the remaining nodal volume. Although an incontrovert-
ible diagnosis would be provided by examination of 5-μm
sections of the whole node, as in sentinel-node techniques,
this is a laborious and costly procedure, and the clinical
relevance of the detection of occult subpathological meta-
static deposits remains unclear [29].
Radiotherapy oncologists have devoted considerable
research efforts to measures for the protection of normaltissues from radiation, with a focus on minimizing their
exposure. However, there have been few attempts to
determine the target volume for irradiation in each
specific situation, and no standardized patterns of lymph
node relapse after postoperative neck radiation therapy
have been established, which may be because target
volumes generally include all lymph nodes on both sides
of the neck. To our best knowledge, the present inves-
tigation offers one of the few descriptions of a selective
nodal irradiation protocol for patients undergoing sur-
gery for oral cavity and pharyngeal cancer according to
the estimated risk for each nodal level.
Conclusion
In conclusion, nodal involvement in oral cavity and
pharyngeal cancer follows a predictable and gradual
pattern across the different neck levels, supporting the
selective neck irradiation approach. The availability of a
reliable postoperative nodal-involvement pattern by level
allows clinicians to determine target volumes according to
the estimated risk for each nodal level. The neck failure
pattern obtained after a postoperative selective nodal
irradiation protocol does not differ from that obtained after
a standard irradiation protocol. Nodal recurrence is most
frequently detected in high-risk nodal levels receiving high
irradiation doses. The target volume with selective nodal
radiotherapy is significantly lower than the target volume
with a standard nodal radiotherapy protocol.
Selective nodal irradiation of the neck is not yet a
standard treatment. However, greater understanding of
the natural history of the tumors and the availability of
increasingly sophisticated radiotherapy techniques will
facilitate further trials to support oncologists in the opti-
mal selection of high-risk target volumes.
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